长药控股索赔案再获法院立案,天沃科技索赔案已有胜诉进入倒计时
Xin Lang Cai Jing·2026-02-27 01:28

Core Viewpoint - The article discusses the ongoing legal actions against Changyao Holdings (300391) for investor compensation due to financial misconduct, including false reporting of revenues and profits from 2021 to 2023 [1][2][3]. Group 1: Legal Proceedings - Changyao Holdings' investor compensation case has been accepted by the Wuhan Intermediate People's Court, with multiple previous filings also accepted [1]. - The law firm is continuing to accept compensation claims from other investors [1]. - There are precedents of investor victories in similar compensation cases against Changyao Holdings [1]. Group 2: Financial Misconduct - From 2021 to 2023, Changyao Holdings' subsidiaries fabricated inventory and sales documents, leading to inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan, which represented 9.12%, 17.57%, and 19.51% of the reported revenues for those years respectively [2]. - The inflated total profits for the same years were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the reported total profits [2]. - In 2022, the company also inflated profits by 4.55 million yuan due to improper loss recognition related to a project, which was 6.34% of the reported total profits for that year [2]. Group 3: Investor Compensation Eligibility - Investors who purchased Changyao Holdings stock between March 30, 2019, and April 30, 2024, and sold or held the stock after April 30, 2024, are eligible to file for compensation [3]. - Additionally, those who bought shares between April 28, 2022, and November 8, 2025, and sold or held after November 8, 2025, can also initiate claims [3].

THVOW-长药控股索赔案再获法院立案,天沃科技索赔案已有胜诉进入倒计时 - Reportify